Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Gastric cancer (GC) is the third leading cause of cancer-related death worldwide and it mostly develops in long-standing inflammatory conditions, and Helicobacter pylori-gastritis, in particular. Despite the increasing understanding of both the phenotypic alterations and the molecular mechanisms occurring during GC multi-step carcinogenesis, no reliable biomarker is available to be reliably implemented into GC secondary prevention strategies. Multidisciplinary diagnostic approaches integrating endoscopy, serology, histology and molecular profiling currently appears as the most appropriate approach for patients' stratification into different GC risk classes.

More information

DOI

10.1016/j.bpg.2014.09.002

Type

Journal article

Publication Date

01/12/2014

Volume

28

Pages

1043 - 1053

Total pages

10

Keywords

Biomarkers, Gastric cancer, Gastritis, Gastritis staging, Molecular pathology, OLGA, OLGIM, Adenocarcinoma, Biomarkers, Gastritis, Helicobacter Infections, Humans, Precancerous Conditions, Risk Assessment, Stomach Neoplasms